Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Ethnic, racial, and geographic disparities in idiopathic thrombocytopenic purpura related mortality along the US-Mexico border from 1999 to 2020

Allahdad Khan, Sheikh Abdullah, Eaman Fatima et al. Nov 03, 2025 pp. 7991-7991 10.1182/blood-2025-7991

Abstract Background: Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder marked by accelerated platelet destruction and impa...

Transcriptomic profiling of T cell immune states before and after donor lymphocyte infusion in a patient with acute myeloid leukemia

Rachel White, Chirstina Sharkey, Janmejay Vyas et al. Nov 03, 2025 pp. 2566-2566 10.1182/blood-2025-2566

Abstract Background: One of the biggest challenges in optimizing immunotherapy for acute myeloid leukemia (AML) is the inability to predict...

Profiling drug sensitivity in CLL B cells after BTK inhibitor progression using a novel drug panel

Weiguo Han, Emmanuel Contreras Guzman, Aisharya Bhattacharya et al. Nov 03, 2025 pp. 7407-7407 10.1182/blood-2025-7407

Abstract Introduction: Although current clinical treatment approaches targeting Bruton Tyrosine Kinase (BTK) and BCL2, either as monotherapy...

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Sebastian Grosicki, Haris Ali, Haifa Kathrin Al-Ali et al. Nov 03, 2025 pp. 7353-7353 10.1182/blood-2025-7353

Abstract Background: Myelofibrosis (MF) is a myeloproliferative neoplasm driven by dysregulated JAK-STAT activity and inflammatory cytokine...

Synergistic targeting of KMT2A-rearranged AML with combined LSD1 and menin inhibitors

Mina Tayari, Tulasigeri Totiger, Felipe Beckedorff et al. Nov 03, 2025 pp. 3292-3292 10.1182/blood-2025-3292

Abstract KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) is a high-risk subtype of AML associated with poor prognosis and frequent re...

Multi-omics profiling reveals an immunosuppressive microenvironment and PRL-3 as a therapeutic target in myeloma extramedullary disease

Chunxiang Jin, Jianghuan Lu, He Huang et al. Nov 03, 2025 pp. 5710-5710 10.1182/blood-2025-5710

Abstract Background Extramedullary disease (EMD), an aggressive manifestation of multiple myeloma, remains a significant adverse prognostic...

Checkpoint inhibitors improve progression free survival after autologous transplant despite poorer pre-transplant response

Jack Taylor-Stuart, Mark Ethell, Mike Potter et al. Nov 03, 2025 pp. 7134-7134 10.1182/blood-2025-7134

Abstract Introduction The checkpoint inhibitors (CI) nivolumab and pembrolizumab which target PD1 are established treatments for relapsed/re...

The impact of frailty on real world outcomes for multiple myeloma patients in England – a cohort study from the uncover study group and ukmra frailty group.

Thea Chandler, Indrani Karpha, Nurunnahar Akter et al. Nov 03, 2025 pp. 2792-2792 10.1182/blood-2025-2792

Abstract Introduction Evidence for disease outcomes in Multiple Myeloma (MM) is largely derived from clinical trials whi...

Sasp-driven immune evasion defines a novel African ancestry-associated DLBCL subtype with distinctive molecular and immune vulnerabilities

Sanket Shah, Meng Li, Michelle Lee et al. Nov 03, 2025 pp. 3-3 10.1182/blood-2025-3

Abstract Diffuse large B-cell lymphoma (DLBCL) arises at an earlier age and is associated with inferior survival in African American patient...

Investigating ribosome biogenesis in AML identifies MYB-binding protein 1A (MYBBP1A) as an essential regulator of leukemia cells

Phuong To, Bertina Dragunaite, Pedro Casado et al. Nov 03, 2025 pp. 990-990 10.1182/blood-2025-990

Abstract Ribosome biogenesis (Ribi) is essential to cellular function and often deregulated in cancer, making it an attractive therapeutic t...

Epik-L1: A Phase 2/3 study of alpelisib in pediatric and adult patients with PIK3CA-driven lymphatic malformations

Bryan Sisk, Guillaume Canaud, Juan C Lopez-Gutierrez et al. Nov 03, 2025 pp. 4893-4893 10.1182/blood-2025-4893

Abstract Background and Significance: Lymphatic malformations(LyM) are rare, serious conditions, characterized by non-malignant masses consi...

Evaluating flow cytometry (FC) and next generation sequencing (NGS) for assessing minimal residual disease (MRD) and B-cell aplasia (BCA) in children, adolescents and young adults (CAYA) with B-cell acute lymphoblastic leukemia (B-ALL)

Chelsea O'Koren, Julie Ma, Bonnie Yates et al. Nov 03, 2025 pp. 3363-3363 10.1182/blood-2025-3363

Abstract Background: Several biomarkers are utilized to monitor for B-ALL relapse. For minimal residual disease (MRD), these include flow cy...

Improved outcomes following allogeneic hematopoietic stem cell transplantation in patients with DDX41-mutated myeloid neoplasms: A prospective analysis of survival, GVHD, and transplant-related mortality

Shreyas Hanmantgad, Alan Mitchell, Kayleigh Mccloskey et al. Nov 03, 2025 pp. 6083-6083 10.1182/blood-2025-6083

Abstract Introduction: Germline mutations in DDX41 represent a unique subgroup of hereditary myeloid neoplasms, most commonly acute myeloid...

Safety, tolerability and early efficacy of mdc-CAR-BCMA001 – a high affinity BCMA targeting CAR T-cell therapy in patients with multiple myeloma and diffuse large B-cell lymphoma

Jingting Luan, Brigitte Neuber, Carina Wenzel et al. Nov 03, 2025 pp. 2388-2388 10.1182/blood-2025-2388

Abstract Background: BCMA is a validated target for T-cell engagers and chimeric antigen receptor (CAR) T-cell therapy i...

Analysis of published case reports on lymphoma using llms

Fabio Dennstaedt, Alin Handra, Nikola Cihoric Nov 03, 2025 pp. 8215-8215 10.1182/blood-2025-8215

Abstract Introduction: Lymphoma represents a diverse group of cancers with heterogeneous presentations, making treatment decisions complex....

Chidamide-BEAM conditioning plus autologous stem cell transplantation forperipheral t-cell lymphoma: A single-arm, single-center, phase 2 trial

Meng-Meng Ji, Yige Shen, Siyuan Chen et al. Nov 03, 2025 pp. 3631-3631 10.1182/blood-2025-3631

Abstract Chidamide-BEAM Conditioning plus Autologous Stem Cell Transplantation for Peripheral T-cell Lymphoma: A single-arm, single-center, phase 2 trial...

Marvin: Deep generative model with structured latent space for flow cytometry cell classification and discovery of new population

Adrien De Voeght, Fanny Bodart, Frédéric Baron et al. Nov 03, 2025 pp. 6132-6132 10.1182/blood-2025-6132

Abstract BACKGROUND Mass or flow cytometry are used in research and clinical settings to analyze cell populations. It generates multidimensi...

T-lymphoblastic lymphoma presenting as pericardial tamponade: A rare initial manifestation of an aggressive malignancy

Mohammed Aloqaily, Laith Rhabneh, Ra'ed Ababneh et al. Nov 03, 2025 pp. 6849-6849 10.1182/blood-2025-6849

Abstract Background: T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) is a rare, aggressive neoplasm of precursor T-cells, typically affecting...

Baseline cytomegalovirus IgG levels predict reactivation in patients with multiple myeloma receiving elranatamab

Ukyo Kondo, Taku Kikuchi, Shotaro Sugita et al. Nov 03, 2025 pp. 5753-5753 10.1182/blood-2025-5753

Abstract Background: Elranatamab is a bispecific antibody approved for patients with triple-class exposed relapsed or refractory multiple my...

Intrathecal chemotherapy for management of immune effector cell-associated neurotoxicity syndrome (ICANS): A multi-center, real-world analysis of clinical outcomes

Adam Kidwell, Karolina Lungova, Anikó Szabó et al. Nov 03, 2025 pp. 6302-6302 10.1182/blood-2025-6302

Abstract Background Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of large B-cell lymphoma (LBCL) but is l...

A unified nanopore-based approach for direct telomere sequencing and genetic diagnosis in inherited bone marrow failure syndromes

Shota Kato, Hirohisa Yajima, Aiko Sato-Otsubo et al. Nov 03, 2025 pp. 4990-4990 10.1182/blood-2025-4990

Abstract Introduction: Telomeres are repetitive sequences located at the ends of chromosomes. Impaired telomere maintenance in telomere biol...

NOXA modulates tipifarnib sensitivity in myeloid leukemia cells.

Traci Kruer, Lei Sun, Ariel Quintana et al. Nov 03, 2025 pp. 6956-6956 10.1182/blood-2025-6956

Abstract Tipifarnib is a potent small-molecule farnesyltransferase inhibitor (FTI) that has demonstrated single-agent activity in acute myel...

FLT3-ITD mutation promotes leukemic differentiation toward an immature cytotoxic stage

Allana Guimarães de Carvalho, Mariana Medeiros, Camila Garcia et al. Nov 03, 2025 pp. 1703-1703 10.1182/blood-2025-1703

Abstract FLT3 mutations contribute to leukemogenesis and poor prognosis in acute myeloid leukemia (AML). Despite FLT3-targeted therapies, re...

Tailoring TBI for vulnerable patients: 8 gy TBI shows comparable outcomes to 12 gy TBI in adult ALL allo-HSCT

Tomoyo Kubo, Shinsuke Takagi, Mika Kuno et al. Nov 03, 2025 pp. 5971-5971 10.1182/blood-2025-5971

Abstract Introduction: Total body irradiation (TBI) is a standard component of conditioning regimens for allogeneic hematopoietic stem cell...

Spen loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and TLR pathway therapeutic vulnerabilities

Benedikt Pelzer, Cem Meydan, Isaac Spiegel et al. Nov 03, 2025 pp. 140-140 10.1182/blood-2025-140

Abstract Diffuse large B cell lymphomas (DLBCL) are the most common lymphoid malignancies in adults. Despite advances in molecular classific...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page